Form 4: Ocular Therapeutix Chief Strategy Officer Sells Shares to Cover Tax Obligations

Ocular Therapeutix's Chief Strategy Officer, Sanjay Nayak, sold 1,862 shares of common stock on May 23, 2025, at a weighted average price of $7.17, to satisfy tax withholding obligations related to RSU vesting.

Summary

• Sanjay Nayak, Chief Strategy Officer of Ocular Therapeutix, Inc. (OCUL), reported a sale of common stock.
• The transaction involved 1,862 shares sold on May 23, 2025.
• The shares were sold at a weighted average price of $7.17, with prices ranging from $7.06 to $7.28.
• The sale was executed under a Rule 10b5-1 plan adopted on February 21, 2024.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) on May 22, 2025.
• This was a non-discretionary trade by the reporting person.
• Following the transaction, Mr. Nayak beneficially owns 281,623 shares of Ocular Therapeutix common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell-to-cover' to satisfy tax obligations related to RSU vesting, which is a neutral event for stock sentiment as it does not indicate a change in management's confidence in the company.

Positives

• The sale was non-discretionary, executed under a pre-arranged 10b5-1 plan, indicating it was not a market timing decision based on insider information.
• The transaction stemmed from the vesting of restricted stock units, which represents a form of compensation for the Chief Strategy Officer.

Negatives

• No direct negatives identified as the sale was for tax purposes and not a discretionary divestment.

Future Outlook

NA

Management Comments

• The sales do not represent a discretionary trade by the reporting person.
• Represents shares of common stock of Ocular Therapeutix, Inc. sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2025.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction, specifically a non-discretionary 'sell-to-cover' sale, which is common practice across industries for executives receiving equity compensation. It does not provide insights into broader industry trends for the pharmaceutical or ophthalmology sectors.

Stakeholder Impact

• Shareholders: The sale is a routine tax-related transaction and does not signal a change in management's outlook, thus having minimal direct impact.
• Employees: The vesting of RSUs is a form of compensation, which is generally positive for employee retention and motivation.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request from the Corporation or the SEC staff.

Key Dates

Keywords

Ocular Therapeutix, OCUL, Form 4, insider trading, stock sale, Sanjay Nayak, Chief Strategy Officer, restricted stock units, RSU, 10b5-1 plan, tax withholding